Tryp Therapeutics Inc. TRYPF Archives - Page 7 of 8

ThursdayJun 24, 2021 10:17 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the company and its drug development pipeline, with his presentation scheduled to begin at 11:50 a.m. ET. In addition, McKee will contribute to a panel discussion on the future of research and development activities for psychedelic drug compounds. To view the full press release, visit https://ibn.fm/aVFHv…

ThursdayJun 17, 2021 10:39 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced that chairman and CEO Greg McKee was interviewed on the most recent episode of the Stock2Me Podcast. The podcast features a fascinating array of companies and individuals that are actively revolutionizing business practices within their respective markets. In the interview, McKee talked about the objective of TRYP, which is fundamentally to help patients, as well as identifying and bringing new therapies to patients. McKee also discussed the need for innovation in the psychedelics space and Tryp’s upcoming human clinical…

WednesdayJun 16, 2021 10:38 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference Tryp’s synthetic psychedelic drug candidate will be further developed in an upcoming phase 2a clinical study in partnership with pediatric eating disorders expert Jennifer Miller, M.D. at the University of Florida The trial will focus on Tryp’s flagship candidate, TRP-8802, in treating binge eating and hypothalamic obesity The company expects to begin manufacturing its…

TuesdayJun 15, 2021 1:58 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients,” reads a recent article. The piece quotes Tryp President and Chief Science Officer Jim Gilligan as saying, “In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in…

ThursdayJun 10, 2021 10:43 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021 As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases. As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic…

TuesdayJun 08, 2021 12:03 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) Announces Participation at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be presenting at the upcoming Ladenburg Thalmann Healthcare Conference. The all-virtual conference is scheduled for July 13–14, 2021. Tryp chair and CEO Greg McKee, president and chief science officer Jim Gilligan and CFO Luke Hayes will participate in the presentation. The presentation will include an overview of the company, including its pipeline, strategy and business highlights. The company executives will also participate in an analyst-led fireside chat. The presentation is scheduled for Tuesday, July…

ThursdayJun 03, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin

Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials The company intends to contribute to the growing body of research through academic collaborations with leading American institutions The research will focus on indications that other pharmaceutical companies have largely ignored Although we can accurately describe the psychedelics industry as nascent, psychedelics have been the subject of a flurry of groundbreaking research that have gradually lifted the stigma surrounding…

WednesdayJun 02, 2021 11:47 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) to Present at Upcoming H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, has announced that it will be presenting at H.C. Wainwright & Co.’s Psychedelics in Psychiatry and Beyond conference. The virtual event will be held on June 17, 2021. At the elite conference, Tryp chair and CEO Greg McKee will present an overview of the business including the company’s pipeline, which features its psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program for chronic pain and eating disorder indications. McKee’s prerecorded presentation will be available beginning 7 a.m. EDT…

FridayMay 28, 2021 11:34 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances

Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021 Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and capital markets to draw on in developing its product The company is also working with pharmaceutical partners whose diversity of experience will provide support for Tryp’s path to oral psilocybin development Bio-pharmaceutical…

TuesdayMay 25, 2021 9:58 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnership with CDMO Alcami for Exclusive Producg Formulation

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways, has entered into an agreement with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (“CDMO”). The agreement marks Tryp’s next step in the proprietary manufacturing, formulation and delivery of products for its Psilocybin-for-Neuropsychiatric Disorder, PFN(TM) (“PFN”) program. The agreement is focused on developing oral formulations for Tryp’s proprietary psilocybin active pharmaceutical ingredient (“API”), which is being manufactured by Albany Molecular Research, Inc. The announcement noted Alcami’s broad capabilities, technical expertise and ability…

Site Search

Company Search

Tag: Tryp Therapeutics Inc. TRYPF